Skip to main content
Fig. 1 | BMC Women's Health

Fig. 1

From: Expression levels of MCP-1, HGF, and IGF-1 in endometriotic patients compared with non-endometriotic controls

Fig. 1

Serum and peritoneal fluid concentrations of MCP-1 and its gene and protein expression by PFMCs, PBMCs and ESCs. Serum concentrations of MCP-1 were measured in 70 endometriotic and 70 non-endometriotic participants. Peritoneal fluid concentrations of MCP-1 were measured in 36 endometriotic and 30 non-endometriotic participants. The basal gene and protein expression of MCP-1 were measured in PFMCs (n = 10), PBMCs (n = 10), EESCs (n = 8), and EuESCs (n = 10) from patients with endometriosis and PFMCs (n = 7), PBMCs (n = 10), and CESCs (n = 10) from non-endometriotic women. (Aa) serum concentration of MCP-1, (Ab) peritoneal concentration of MCP-1, (Ac) serum concentration of MCP-1 in different stages of endometriosis, (Ad) serum concentration of MCP-1 in different menstrual cycles, (Ba) MCP-1 gene expression by PFMCs, (Bb) MCP-1 protein expression by PFMCs, (Bc) MCP-1 gene expression by PBMCs, (Bd) MCP-1 protein expression by PBMCs, (Be) MCP-1 gene expression by ESCs, (Bf) MCP-1 protein expression by ESCs. *P < 0.05, **P < 0.01, ***P < 0.001. A and B parts analyzed by parametric and non-parametric tests, respectively. †P–C: Proliferative phase of the control group, S-C: Secretory phase of the control group, P–E: Proliferative phase of endometriosis patients, S-E: Secretory phase of endometriosis patients

Back to article page